On January 14, 2026, Penumbra Inc. announced its agreement to merge with Boston Scientific Corporation, where Penumbra will become a wholly owned subsidiary. Each share will convert to either 3.8721 shares of Boston Scientific or $374 in cash, with 73.26% of shares converting to cash and the remainder to stock.